These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18559614)

  • 1. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A; Seshadri M; Oven SD; Tóth K; Vaughan MM; Rustum YM
    Clin Cancer Res; 2008 Jun; 14(12):3926-32. PubMed ID: 18559614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
    Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
    Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.
    Bhattacharya A; Tóth K; Sen A; Seshadri M; Cao S; Durrani FA; Faber E; Repasky EA; Rustum YM
    Clin Colorectal Cancer; 2009 Jul; 8(3):155-62. PubMed ID: 19632930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.
    Li Z; Carrier L; Belame A; Thiyagarajah A; Salvo VA; Burow ME; Rowan BG
    Breast Cancer Res Treat; 2009 Nov; 118(1):33-43. PubMed ID: 18855134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Azrak RG; Cao S; Durrani FA; Toth K; Bhattacharya A; Rustum YM
    Cancer Lett; 2011 Dec; 311(2):219-29. PubMed ID: 21872389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.
    Bhattacharya A; Turowski SG; San Martin ID; Rajput A; Rustum YM; Hoffman RM; Seshadri M
    Anticancer Res; 2011 Feb; 31(2):387-93. PubMed ID: 21378316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs.
    Bhattacharya A
    Expert Opin Drug Deliv; 2011 Jun; 8(6):749-63. PubMed ID: 21473705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Fakih M; Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jul; 5(2):132-5. PubMed ID: 16098255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
    Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
    Imai A; Zeitlin BD; Visioli F; Dong Z; Zhang Z; Krishnamurthy S; Light E; Worden F; Wang S; Nör JE
    Cancer Res; 2012 Feb; 72(3):716-25. PubMed ID: 22158856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG; Cao S; Pendyala L; Durrani FA; Fakih M; Combs GF; Prey J; Smith PF; Rustum YM
    Biochem Pharmacol; 2007 May; 73(9):1280-7. PubMed ID: 17239826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.
    van Herpen CM; Bussink J; van der Kogel AJ; Peeters WJ; van der Voort R; van Schijndel A; de Wilde PC; Adema GJ; de Mulder PH
    Anticancer Res; 2005; 25(2A):1015-21. PubMed ID: 15868941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S; Durrani FA; Tóth K; Rustum YM
    Br J Cancer; 2014 Apr; 110(7):1733-43. PubMed ID: 24619073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
    Seshadri M; Sacadura NT; Coulthard T
    Angiogenesis; 2011 Dec; 14(4):491-501. PubMed ID: 21901534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.